Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/5/2019
SIETES contiene 92751 citas

 
 
 1 a 20 de 428 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Haight BR, Learned SM, Lafont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Linq W, Heidbreder C, RB-US-13-0001 Study Investigators. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393:23 de febrero. [Ref.ID 103111]
2.Enlace a cita original Cita con resumen
Hedenmalm K, Slattery J, Skibicka-Stepien I, Kurz X, Morales D. Prescribing patterns of tramadol in adults in IMS® primary care databases in France and Germany between 1 January 2006 and 30 June 2016. Eur J Clin Pharmacol 2019;75:5. [Ref.ID 103092]
3.Enlace a cita original Cita con resumen
Bonovas S, Nikolopoulos GK, Lytras T, Fiorino G, Peyrin-Biroulet L, Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis . Br J Clin Pharmacol 2018;84:febrero. [Ref.ID 102533]
4. Cita con resumen
Herzig SJ, Mosher HJ, Calcaterra SL, Jena AB, Nuckols TK. Improving the safety of opioid use for acute noncancer pain in hospitalized adults: a consensus statement from the Society of Hospital Medicine. J Hosp Med 2018;13:abril. [Ref.ID 102501]
5. Cita con resumen
6. Cita con resumen
Iacobucci G. NHS to stop funding homeopathy and some drugs in targeted savings drive. BMJ 2017;358:j3560. [Ref.ID 102013]
7. Cita con resumen
Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Benedetto U. Tolerability of new antiepileptic drugs: a network meta-analysis. Eur J Clin Pharmacol 2017;73:811-7. [Ref.ID 101994]
8. Cita con resumen
Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]
9. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
10. Cita con resumen
Shaheed CA, Maher CG, Williams KA, Day R, McLachlan AJ. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med 2016;176:958-68. [Ref.ID 100298]
11.Tiene citas relacionadas Cita con resumen
Chan E, Fogler JM, Hammemess PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA 2016;315:1997-2008. [Ref.ID 100290]
13. Cita con resumen
Anónimo. Guanfacine for ADHD in children and adolescents. Drug Ther Bull 2016;54:56-60. [Ref.ID 100276]
14. Cita con resumen
Anónimo. ‘Sí’ de la EMA a palmitato de paliperidona, de Janssen, en presentación trimestral. Correo Farmacéutico 2016:17. [Ref.ID 100109]
15.Tiene citas relacionadas Cita con resumen
Katz MH. Opioid prescribing for chronic pain. Not for the faint of heart . JAMA Intern Med 2016;176:599-601. [Ref.ID 100104]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dowell D, Haegerich TM. CDC guideline for prescribing opioids for chronic pain — United States, 2016. JAMA 2016;315:15 de marzo. [Ref.ID 100030]
17. Cita con resumen
Anónimo. Two long-acting injectable antipsychotics for schizophrenia. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:152-3. [Ref.ID 99815]
18. Cita con resumen
Gwynn J. Pregabalin is only partially effective for neuropathic pain. BMJ 2015;350:h3478. [Ref.ID 99221]
19. Cita con resumen
Anónimo. Aripiprazole injectable à libération prolongée. Prescrire 2015;35:252-3. [Ref.ID 99124]
20. Cita con resumen
Miller M, Barber CW, Leatherman S, Fonda J, Hemos JA, Cho K, Gagnon DR. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med 2015;175:608-15. [Ref.ID 99011]
Seleccionar todas
 
 1 a 20 de 428 siguiente >>